Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAXAK: HPV Vaccine in Actinic Keratosis
NCT05202860Phase 2Active, not recruiting
- Start
- May 2022
- Primary completion
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human papillomavirus 9-valent vaccine in actinic keratosis (AK). Started May 2022; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT05202860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05202860.